 October,
2003 - Denver, CO. The new oral medications for impotence may elicit
different responses in different men, ie, failure to respond to one
does not necessarily mean all will fail, according to data presented
at the annual meeting of the Sexual Medicine Society of North America
. Among 450 men who failed to respond to Viagra, even after six or more
attempts at the 100 mg dose, Levitra yielded erectile benefits in many.
 The
study was a randomized trial of placebo vs vardenafil (Levitra) in 450
men who had failed to respond to Viagra, using various measures of efficacy,
including ability to penetrate, ability to maintain, the key erectile
function domain score, and an overall assessment. All showed statistically
significant improvements with Levitra, compared to the placebo responses.
Side effects included the now-familiar class effects of headache, flushing,
nasal stuffiness, and dyspepsia, as noted in many other reports.
The converse study, a trial of Viagra in men who failed
Levitra, would have been of interest, but was not performed. At present,
we conclude that, for many men, a trial of another of the 3 available
PDE-5 inhibitors (Levitra,
Viagra, Cialis),
is a reasonable alternative when one fails.
Slides from the SMSNA presentation are available here.
USRF
Special Report: Viagra vs the New PDE-5 Inhibitors
RELATED LINKS:
|
